A 779 TFA is primarily used as a selective antagonist for the angiotensin II type 2 (AT2) receptor in research settings. It helps in studying the physiological and pathological roles of the renin-angiotensin system, particularly in cardiovascular and renal functions. Due to its specificity, it is employed in experimental models to differentiate AT2 receptor-mediated effects from those acting through the AT1 receptor. It is commonly used in studies related to blood pressure regulation, inflammation, tissue injury, and fibrosis. Its application extends to in vitro assays and in vivo animal models where modulation of angiotensin signaling is required to understand disease mechanisms or evaluate potential therapeutic targets.